Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | CASR | P41180 | 18/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluproquazone SCHEMBL29363976 | 1.00 | NR1I2 (0.77) | NR1I2EGFRADRA2AADORA3TBXA2R | |
| SCHEMBL11565990 | 0.92 | NR1I2 (0.85) | NR1I2EGFRADRA2AADORA3TBXA2R | |
| SCHEMBL11723933 | 0.87 | NR1I2 (0.77) | NR1I2EGFRADRA2AADORA3TBXA2R | |
| Proquazone SCHEMBL29508590 | 0.87 | NR1I2 (1.00) | NR1I2EGFRADRA2AADORA3TBXA2R | |
| Proquazone SCHEMBL25341 | 0.87 | NR1I2 (1.00) | NR1I2EGFRADRA2AADORA3TBXA2R | |
| Proquazone SCHEMBL2931942 | 0.86 | NR1I2 (0.97) | NR1I2EGFRADRA2AADORA3TBXA2R | |
| Fluproquazone SCHEMBL11080399 | 0.84 | NR1I2 (0.61) | NR1I2EGFRADRA2AADORA3TBXA2R | |
| SCHEMBL11726950 | 0.83 | NR1I2 (0.54) | NR1I2EGFRADRA2AADORA3TBXA2R | |
| SCHEMBL11608840 | 0.81 | NR1I2 (0.67) | NR1I2EGFRADRA2AADORA3TBXA2R | |
| SCHEMBL11605525 | 0.79 | NR1I2 (0.76) | NR1I2EGFRADRA2AADORA3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1912 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-3998932-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | Parsons, C. Lowell (US) | 2022-05-25 | — | — | EP | claimed |
| US-20220088158-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ROIVANT SCIENCES, INC. | 2022-03-24 | — | — | US | claimed |
| WO-2021011566-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | PARSONS C LOWELL (US) | 2021-01-21 | — | — | WO | claimed |
| WO-2020152532-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ENZYVANT THERAPEUTICS GMBH (CH) | 2020-07-30 | — | — | WO | claimed |
| EP-3609483-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | Urigen Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| WO-2018191412-A9 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2019-05-31 | — | — | WO | claimed |
| WO-2018191412-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| US-20160113936-A1 | METHODS FOR MODULATING MONOCYTE FUNCTION | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2016-04-28 | — | — | US | claimed |
| WO-2004082719-A1 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040156872-A1 | Novel nimesulide compositions | ELAN PHARMA INTERNATIONAL LTD. | 2004-08-12 | — | — | US | claimed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003066029-A2 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| WO-2003066030-A2 | PHARMACEUTICAL TABLET | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| US-4442084-A | ABSORPTION, LIQUID PHASE CLAUS PROCESS, RECYCLING | SANDOZ LTD. (CH) | 1984-04-10 | — | — | US | claimed |
| US-4236006-A | Preparation of quinazolin-2(1H)-ones | SANDOZ LTD. (CH) | 1980-11-25 | — | — | US | claimed |
| US-4224328-A | Methods with 1-substituted-4-aryl-quinazolin-2(1H)-ones and thiones and pyrido[2,3-d]pyrimidin-2-ones as platelet aggregation inhibitors | SANDOZ, INC. (US) | 1980-09-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156872-A1 | Novel nimesulide compositions | NIM1K, NIT2, NCL | NR1I2 3919/4885EGFR 2788/4885ADRA2A 3740/4885 |
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | NR1I2 1613/4885EGFR 4459/4885ADRA2A 1648/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | NR1I2 1375/4885EGFR 2803/4885ADRA2A 1503/4885 |
| US-20160113936-A1 | METHODS FOR MODULATING MONOCYTE FUNCTION | CD14, HSP90AB2P, HSP90AB1 | NR1I2 967/4885EGFR 4841/4885ADRA2A 2670/4885 |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ASAH2, ASAH1, GBA2 | NR1I2 1617/4885EGFR 4492/4885ADRA2A 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.